| The initial public offer (IPO) of Speciality Medicines received bids for 18,38,000 shares as against 23,50,000 shares on offer, as per BSE data as of 17:00 hours on Friday (20 March 2026). The issue was subscribed 0.78 times.
The issue opened for bidding on Friday (20 March 2026) and it will close on Tuesday (24 March 2026). The price band of the IPO was fixed between Rs 117 to Rs 124 per share. The minimum order quantity is 1,000 equity shares. The equity shares will list on BSE’s SME platform.
The IPO comprises fresh issue of 23,50,000 equity shares. About 1,50,000 equity shares will be reserved for subscription by market maker to the issue. The net issue comprises of 22,00,000 equity shares.
The issue and the net issue will constitute 26.75% and 25.04%, respectively of the post issue paid up equity share capital of the company.
The company intends to utilise the net proceeds for setting up a research and development (R&D) centre at Revenue City Survey No. RV1/NA/61/1/50, Moje Manda, Tal. Umargam, Dist. Valsad, Gujarat; product registration in international markets; product development for sale in international markets; funding marketing and promotional activities; meeting working capital requirements and for general corporate purposes.
Speciality Medicines is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions across therapeutic areas such as oncology, immunology, neurology, and rare diseases. The company offers a diverse portfolio of specialty pharmaceutical products, focusing on these therapeutic areas. Its products are available in a wide range of dosage forms, including tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalations, inhalers, injections, nasal sprays, ointments, ophthalmic preparations, oral solutions, oral suspensions, sachets, and suspensions. The company operates through two integrated business models: (a) manufacturing, on a contract manufacturing basis, approved finished formulations for international distribution; and (b) marketing and distribution of specialty pharmaceutical products sourced from manufacturers. As of 28 February 2026, the company had a total of 18 permanent employees across various departments.
The company recorded revenue from operations of Rs 36.72 crore and net profit of Rs 6.06 crore for the period ended 31 October 2025.
|